GlassScriptPhysician profile
Herman B Kleinbaum
NPI 1528069093
$1,169.21
in general payments reported to CMS, 2019-2025
15 companies · $16.72 in 2025
The $16.72 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $749 · 2020: $199 · 2021: $85.57 · 2022: $54.66 · 2024: $63.99 · 2025: $16.72.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $80.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $80.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $283.51 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $188.84 | 2019-2022 | |
| Abbvie INC. | $186.93 | 2019-2021 | |
| Allergan, INC. | $112.07 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $94.17 | 2019-2024 | Entyvio |
| Concordia Pharmaceuticals INC. | $59.08 | 2019 | |
| Ucb, INC. | $52.19 | 2019-2020 | |
| Janssen Biotech, INC. | $46.52 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $34.83 | 2019-2020 | |
| Amarin Pharma, INC. | $29.57 | 2019 | |
| Olympus America INC. | $20.22 | 2024 | Endoclot Phs |
| Ferring Pharmaceuticals INC. | $17.43 | 2019 | |
| Boston Scientific Corporation | $16.72 | 2025 | Exalt Model D |
| Merck Sharp & Dohme LLC | $15.21 | 2020 | |
| Alfasigma USA, INC. | $11.92 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Herman Kleinbaum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.